Journal of Neuroimmunology
Volume 225, Issue 1 , Pages 22-33 , 25 August 2010

Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions

  • Tony Avril

      Affiliations

    • Département de Biologie, Centre Eugène Marquis, Rennes, France
    • Corresponding Author InformationCorresponding author. Département de Biologie, Centre Eugène Marquis, Rue de la bataille Flandres Dunkerque, CS44229, 35042 Rennes cedex, France. Tel.: +33 299 253 190.
    • ,
  • Stéphan Saikali

      Affiliations

    • Département d'Anatomopathologie, CHU Pontchaillou, Rennes, France
    • ,
  • Elodie Vauleon

      Affiliations

    • Département de Biologie, Centre Eugène Marquis, Rennes, France
    • UMR 6061 CNRS, Université de Rennes 1, IFR 140, Rennes, France
    • ,
  • Anne Jary

      Affiliations

    • Département de Biologie, Centre Eugène Marquis, Rennes, France
    • ,
  • Abderrahmane Hamlat

      Affiliations

    • Département de Neurochirurgie, CHU Ponchaillou, Rennes, France
    • ,
  • Marie De Tayrac

      Affiliations

    • UMR 6061 CNRS, Université de Rennes 1, IFR 140, Rennes, France
    • ,
  • Jean Mosser

      Affiliations

    • UMR 6061 CNRS, Université de Rennes 1, IFR 140, Rennes, France
    • ,
  • Véronique Quillien

      Affiliations

    • Département de Biologie, Centre Eugène Marquis, Rennes, France
    • UMR 6061 CNRS, Université de Rennes 1, IFR 140, Rennes, France

Received 4 January 2010 ,Revised 25 March 2010 ,Accepted 7 April 2010.

References 

  1. Amiot L, Onno M, Drénou B, Monvoisin C, Fauchet R. HLA-G class I gene expression in normal and malignant hematopoietic cells. Hum. Immunol. 1998;59:524–528
  2. Avril T, de Tayrac M, Leberre C, Quillien V. Not all polyriboinosinic–polyribocytidylic acids (Poly I:C) are equivalent for inducing maturation of dendritic cells: implication for alpha-type-1 polarized DCs. J. Immunother. 2009;32:353–362
  3. Bainbridge D, Ellis S, Le Bouteiller P, Sargent I. HLA-G remains a mystery. Trends Immunol. 2001;22:548–552
  4. Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 2008;14:3044–3051
  5. Bodmer S, Strommer K, Frei K, Siepl C, de Tribolet N, Heid I, et al. Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J. Immunol. 1989;143:3222–3229
  6. Brahmer R, Topalian SL, Powderly J, Wollner I, Picus J, Drake CG, et al. Phase II experience with MDX-1106 (Ono-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies. J. Clin. Oncol (Meeting Abstracts). 2009;27:3018
  7. Carosella ED, Favier B, Rouas-Freiss N, Moreau P, Lemaoult J. Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood. 2008;111:4862–4870
  8. Chahlavi A, Rayman P, Richmond AL, Biswas K, Zhang R, Vogelbaum M, et al. Glioblastomas induce T-lymphocyte death by two distinct pathways involving gangliosides and CD70. Cancer Res. 2005;65:5428–5438
  9. Chang CC, Ferrone S. HLA-G in melanoma: can the current controversies be solved? Semin. Cancer Biol. 2003;13:361–369
  10. Constam DB, Philipp J, Malipiero UV, ten Dijke P, Schachner M, Fontana A. Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia. J. Immunol. 1992;148:1404–1410
  11. Corm S, Berthon C, Imbenotte M, Biggio V, Lhermitte M, Dupont C, et al. Indoleamine 2, 3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN-gamma. Leukoc. Res. 2009;33:490–494
  12. Davies B, Hiby S, Gardner L, Loke YW, King A. HLA-G expression by tumors. Am. J. Reprod. Immunol. 2001;45:103–107
  13. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 2002;8:793–800
  14. Eguchi J, Hatano M, Nishimura F, Zhu X, Dusak JE, Sato H, et al. Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses. Cancer Res. 2006;66:5883–5891
  15. Eisele G, Wischhusen J, Mittelbronn M, Meyermann R, Waldhauer I, Steinle A, et al. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain. 2006;129:2416–2425
  16. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 2000;192:1027–1034
  17. Gorelik L, Flavell RA. Transforming growth factor-beta in T-cell biology. Nat. Rev. Immunol. 2002;2:46–53
  18. Grant R, Kapoor V. Inhibition of indoleamine 2, 3-dioxygenase activity in IFN-gamma stimulated astroglioma cells decreases intracellular NAD levels. Biochem. Pharmacol. 2003;66:1033–1036
  19. Gratas C, Tohma Y, Van Meir EG, Klein M, Tenan M, Ishii N, et al. Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol. 1997;7:863–869
  20. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu. Rev Immunol. 2005;23:515–548
  21. Katz JB, Muller AJ, Prendergast GC. Indoleamine 2, 3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol. Rev. 2008;222:206–221
  22. Kikuchi T, Akasaki Y, Abe T, Fukuda T, Saotome H, Ryan JL, et al. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J. Immunother. 2004;27:452–459
  23. Kovats S, Main EK, Librach C, Stubblebine M, Fisher SJ, DeMars R. A class I antigen, HLA-G, expressed in human trophoblasts. Science. 1990;248:220–223
  24. Leitlein J, Aulwurm S, Waltereit R, Naumann U, Wagenknecht B, Garten W, et al. Processing of immunosuppressive pro-TGF-beta 1, 2 by human glioblastoma cells involves cytoplasmic and secreted furin-like proteases. J. Immunol. 2001;166:7238–7243
  25. Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin. Cancer Res. 2005;11:5515–5525
  26. Miyazaki T, Moritake K, Yamada K, Hara N, Osago H, Shibata T, et al. Indoleamine 2, 3-dioxygenase as a new target for malignant glioma therapy. J. Neurosurg. J Neurosurg. 2009;111:230–237
  27. Mkhoyan GG, Ter-Pogossian ZR, Gasparyan MG, Dzhagatspanyan NG, Hovhannesyan GG. Cytokine regulation of immune response in patients with a brain tumor or injury. Neurochem. J. 2008;25:318–319
  28. Munn DH, Mellor AL. Indoleamine 2, 3-dioxygenase and tumor-induced tolerance. J. Clin. Invest. 2007;117:1147–1154
  29. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 1998;281:1191–1193
  30. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 1999;189:1363–1372
  31. Nagata S, Golstein P. The Fas death factor. Science. 1995;267:1449–1456
  32. Nitta T, Ebato M, Sato K, Okumura K. Expression of tumour necrosis factor-alpha, -beta and interferon-gamma genes within human neuroglial tumour cells and brain specimens. Cytokine. 1994;6:171–180
  33. Okano F, Storkus WJ, Chambers WH, Pollack IF, Okada H. Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clin. Cancer Res. 2002;8:2851–2855
  34. Olofsson A, Miyazono K, Kanzaki T, Colosetti P, Engström U, Heldin CH. Transforming growth factor-beta 1, -beta 2, and -beta 3 secreted by a human glioblastoma cell line. Identification of small and different forms of large latent complexes. J. Biol. Chem. 1992;267:19482–19488
  35. Pasche B. Role of transforming growth factor beta in cancer. J. Cell Physiol. 2001;186:153–168
  36. Popko B, Corbin JG, Baerwald KD, Dupree J, Garcia AM. The effects of interferon-gamma on the central nervous system. Mol. Neurobiol. 1997;14:19–35
  37. Qian F, Villella J, Wallace PK, Mhawech-Fauceglia P, Tario JD, Andrews C, et al. Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2, 3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer. Cancer Res. 2009;69:5498–5504
  38. Saas P, Walker PR, Hahne M, Quiquerez AL, Schnuriger V, Perrin G, et al. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?. J. Clin. Invest. 1997;99:1173–1178
  39. Saikali S, Avril T, Collet B, Hamlat A, Bansard JY, Drenou B, et al. Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy. J. Neurooncol. 2007;81:139–148
  40. Soliman HH, Antonia S, Sullivan D, Vanahanian N, Link C, Lee H. Overcoming tumor antigen anergy in human malignancies using the novel indeolamine 2,3-dioxygenase (IDO) enzyme inhibitor, 1-methyl-D-tryptophan (1MT). J. Clin. Oncol. (Meeting Abstracts). 2009;27:3004
  41. Strege RJ, Godt C, Stark AM, Hugo HH, Mehdorn HM. Protein expression of Fas, Fas ligand, Bcl-2 and TGFbeta2 and correlation with survival in initial and recurrent human gliomas. J. Neurooncol. 2004;67:29–39
  42. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–466
  43. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005;352:987–996
  44. Suzuki Y, Claflin J, Wang X, Lengi A, Kikuchi T. Microglia and macrophages as innate producers of interferon-gamma in the brain following infection with Toxoplasma gondii. Int. J. Parasitol. 2004;35:83–90
  45. Taylor AW. Review of the activation of TGF-beta in immunity. J. Leukoc. Biol. 2009;85:29–33
  46. de Tayrac M, Etcheverry A, Aubry M, Saïkali S, Hamlat A, Quillien V, et al. Integrative genome-wide analysis reveals a robust genomic glioblastoma signature associated with copy number driving changes in gene expression. Genes Chromosomes Cancer. 2009;48:55–68
  47. Thomas DA, Massagué J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell. 2005;8:369–380
  48. Uyttenhove C, Pilotte L, Théate I, Stroobant V, Colau D, Parmentier N, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase. Nat. Med. 2003;9:1269–1274
  49. Walker PR, Saas P, Dietrich PY. Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J. Immunol. 1997;158:4521–4524
  50. Walker PR, Calzascia T, Dietrich PY. All in the head: obstacles for immune rejection of brain tumours. Immunology. 2002;107:28–38
  51. Weller M, Fontana A. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain. Brain Res. Brain Res. Rev. 1995;21:128–151
  52. Weller M, Weinstock C, Will C, Wagenknecht B, Dichgans J, Lang F, et al. CD95-dependent T-cell killing by glioma cells expressing CD95 ligand: more on tumor immune escape, the CD95 counterattack, and the immune privilege of the brain. Cell. Physiol. Biochem. 1997;7:282–288
  53. Widner B, Werner ER, Schennach H, Wachter H, Fuchs D. Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin. Chem. 1997;43:2424–2426
  54. Wiendl H, Mitsdoerffer M, Hofmeister V, Wischhusen J, Bornemann A, Meyermann R, et al. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J. Immunol. 2002;168:4772–4780
  55. Wilmotte R, Burkhardt K, Kindler V, Belkouch MC, Dussex G, Tribolet N, et al. B7-homolog 1 expression by human glioma: a new mechanism of immune evasion. Neuroreport. 2005;16:1081–1085
  56. Wintterle S, Schreiner B, Mitsdoerffer M, Schneider D, Chen L, Meyermann R, et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res. 2003;63:7462–7467
  57. Yamanaka R. Cell- and peptide-based immunotherapeutic approaches for glioma. Trends Mol. Med. 2008;14:228–235
  58. Yamanaka R, Abe T, Yajima N, Tsuchiya N, Homma J, Kobayashi T, et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br. J. Cancer. 2003;89:1172–1179
  59. Yamanaka R, Homma J, Yajima N, Tsuchiya N, Sano M, Kobayashi T, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin. Cancer Res. 2005;11:4160–4167
  60. Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 2004;64:4973–4979
  61. Zhang JG, Eguchi J, Kruse CA, Gomez GG, Fakhrai H, Schroter S, et al. Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics. Clin. Cancer Res. 2007;13:566–575

PII: S0165-5728(10)00157-8

doi: 10.1016/j.jneuroim.2010.04.003

Journal of Neuroimmunology
Volume 225, Issue 1 , Pages 22-33 , 25 August 2010

Article Tools

* Image Usage & Resolution